SLC5A2 and diabetic kidney disease: These findings suggest that incretin mimetics and SGLT2 inhibitors have advantages over traditional hypoglycemic drugs in hypoglycemic and renoprotective effects, and with the advent of novel agents, they are expected to be alternative options for patients with DM or DKD.